Compare STXS & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STXS | SWKH |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.0M | 205.9M |
| IPO Year | 2004 | 1999 |
| Metric | STXS | SWKH |
|---|---|---|
| Price | $2.68 | $17.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 571.4K | 8.7K |
| Earning Date | 03-02-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | $30,075,000.00 | ★ $40,149,000.00 |
| Revenue This Year | $24.21 | $52.93 |
| Revenue Next Year | $29.83 | N/A |
| P/E Ratio | ★ N/A | $9.38 |
| Revenue Growth | 19.62 | ★ 62.38 |
| 52 Week Low | $1.54 | $13.17 |
| 52 Week High | $3.59 | $20.49 |
| Indicator | STXS | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 56.34 |
| Support Level | $2.59 | $17.10 |
| Resistance Level | $2.82 | $17.63 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 63.21 | 68.42 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.